Home » Stocks » DCTH

Delcath Systems, Inc. (DCTH)

Stock Price: $12.80 USD 0.13 (1.03%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
Market Cap 80.02M
Revenue (ttm) 1.65M
Net Income (ttm) -24.21M
Shares Out 2.90M
EPS (ttm) -8.36
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $12.80
Previous Close $12.67
Change ($) 0.13
Change (%) 1.03%
Day's Open 12.70
Day's Range 12.36 - 12.89
Day's Volume 181,742
52-Week Range 6.06 - 25.18

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

20.1% Lower Bound of Preliminary ORR Analysis Exceeds Required 8.3% Threshold 20.1% Lower Bound of Preliminary ORR Analysis Exceeds Required 8.3% Threshold

2 weeks ago - GlobeNewsWire

Shares of Delcath Systems (NASDAQ:DCTH) were unchanged after the company reported Q4 results. Quarterly Results Earnings per share were down 1400.00% over the past year to ($0.60), which beat the estima...

2 weeks ago - Benzinga

Delcath Systems Inc (NASDAQ: DCTH) has announced top-line preliminary results from the Phase 3 FOCUS trial of Hepzato Kit (melphalan hydrochloride for injection/hepatic delivery system) in patients with...

2 weeks ago - Benzinga

NEW YORK, March 31, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today repor...

2 weeks ago - GlobeNewsWire

Based on Preliminary Data, FOCUS Trial Achieves Prespecified Success Threshold

2 weeks ago - GlobeNewsWire

NEW YORK, March 24, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announ...

3 weeks ago - GlobeNewsWire

NEW YORK, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq:  DCTH ), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, annou...

2 months ago - GlobeNewsWire

NEW YORK, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq:  DCTH   ), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, ann...

3 months ago - GlobeNewsWire

NEW YORK, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today a...

4 months ago - GlobeNewsWire

NEW YORK, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today a...

4 months ago - GlobeNewsWire

NEW YORK, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announ...

4 months ago - GlobeNewsWire

Delcath Systems, Inc. (DCTH) CEO Gerard Michel on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

NEW YORK, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of primary and metastatic cancers, today announce...

5 months ago - GlobeNewsWire

NEW YORK, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of primary and metastatic cancers, today announce...

5 months ago - GlobeNewsWire

Overall Response Rate of 72% observed in patients with metastases confined to the liver Overall Response Rate of 72% observed in patients with metastases confined to the liver

5 months ago - GlobeNewsWire

NEW YORK, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH) today announced that the Board of Directors appointed Gerard Michel as Chief Executive Officer, effective October 1, 2020...

6 months ago - GlobeNewsWire

Safety data of early part of FOCUS trial have been publicly disseminated.

6 months ago - Seeking Alpha

NEW YORK, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of rare primary and metastatic cancers, today ...

7 months ago - GlobeNewsWire

Wall Street recommends to buy shares of SenesTech Inc (NASDAQ:SNES) and Delcath Systems Inc (NASDAQ:DCTH), even though these two stocks have disappointed so much over the prior 52 weeks through Monday, ...

Other stocks mentioned: SNES
7 months ago - GuruFocus

NEW YORK, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of rare primary and metastatic cancers, today a...

7 months ago - GlobeNewsWire

Delcath Systems, Inc. (DCTH) CEO John Purpura on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

NEW YORK, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of rare primary and metastatic cancers, today a...

8 months ago - GlobeNewsWire

NEW YORK, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of rare primary and metastatic cancers, today a...

8 months ago - GlobeNewsWire

NEW YORK, May 26, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of rare primary and metastatic cancers, today an...

10 months ago - GlobeNewsWire

Highlights include $22 million public offering, uplisting to Nasdaq, Pivotal Registration Trial enrollment completed, and Pivotal Registration Topline Data Expected in 2020

11 months ago - GlobeNewsWire

NEW YORK, May 05, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today ...

11 months ago - GlobeNewsWire

NEW YORK, May 01, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH  NASDAQ:DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the li...

11 months ago - GlobeNewsWire

About DCTH

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO includes the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective respon... [Read more...]

Industry
Medical Devices
Founded
1988
CEO
Jennifer Simpson
Employees
36
Stock Exchange
NASDAQ
Ticker Symbol
DCTH
Full Company Profile

Financial Performance

In 2020, DCTH's revenue was $1.65 million, an increase of 4.18% compared to the previous year's $1.58 million. Losses were -$24.16 million, 172.1% more than in 2019.

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for DCTH stock is "Buy." The 12-month stock price forecast is 22.75, which is an increase of 77.73% from the latest price.

Price Target
$22.75
(77.73% upside)
Analyst Consensus: Buy